SCHENECTADY, N.Y., Aug. 2 /PRNewswire/ -- CardioMag Imaging, Inc. (CMI) is pleased to announce receipt of two (2) additional patents; one in the United States and one in China to protect key aspects of its technology that can, non-invasively, safely, rapidly and more reliably than ECG, detect early symptoms of Heart Disease without the use of injections or Radiation.

The U.S. Patent, entitled USE OF MACHINE LEARNING FOR CLASSIFICATION OF MAGNETO CARDIOGRAMS, was applied for on July 1, 2003, while the patent application for China was submitted on December 30, 2005 and is entitled METHOD FOR CLASSIFYING CARDIOGRAPHY DATA.

For the past ten years, the Company has developed and tested the value of its MagnetoCardioGraphy (MCG) system in clinical hospital settings in the United States, Europe and China. Results of many of these tests, including moving color maps reflecting heart beat variations, have been presented and published in several dozen medical society meetings and medical journals.

The Company’s MCG system is enabled through the use of an array of Superconducting Quantum Interference Devices (SQUIDS) and has received FDA clearance, the CE Mark for Europe and approved for sale in Russia and China.

The objective of these patents is to improve and facilitate human interpretation of real-time MCG diagnostic testing results based upon computer processing aided artificial intelligence.

CardioMag expects, upon securing Insurance Company Reimbursement Payment Schedules for the 10-minute test, to greatly expand the use in the U.S. of MCG systems for screening, since MCG screenings can save many lives and Billions of Dollars in HealthCare costs as well as monitor both the efficacy of pharmacological treatments and recovery from invasive cardiac procedures.

CardioMag Imaging, Inc., formed in 1999 to transition results from over 30 years of worldwide MCG research and development into commercially useful and attractive SQUID (Superconducting Quantum Interference Device) based products. The company is positioning itself to provide lifesaving and medical cost containment solutions to the cardiac health care community by designing, manufacturing and marketing innovative imaging and medical diagnostic devices for early detection of heart disease.

Safe Harbor Statement: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as CardioMag or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other words or phrases of similar import. Similarly, statements herein that describe CardioMag’s business strategy, outlook, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain assumptions, risks and uncertainties, and other factors set forth here, including but not limited to, obtaining FDA approval, market acceptance, insurance companies reimbursement policies on particular diagnostic applications and the growth of customer acceptance that could cause actual results to differ materially from those in forward-looking statements.

SOURCE CardioMag Imaging, Inc.